- Home
- JMSB vs ACRS Comparison
JMSB vs ACRS Comparison
Compare JMSB & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JMSB | ACRS |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.3M | 314.2M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | JMSB | ACRS |
|---|---|---|
| Price | $20.02 | $3.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $22.50 | $9.75 |
| AVG Volume (30 Days) | 20.0K | ★ 3.1M |
| Earning Date | 01-28-2026 | 02-23-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | ★ 24.17 | N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | ★ $60,950,000.00 | $15,742,000.00 |
| Revenue This Year | $15.30 | N/A |
| Revenue Next Year | $9.72 | N/A |
| P/E Ratio | $13.42 | ★ N/A |
| Revenue Growth | ★ 13.53 | N/A |
| 52 Week Low | $13.81 | $1.05 |
| 52 Week High | $21.58 | $4.89 |
Technical Indicators
Market Signals| Indicator | JMSB | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 46.11 | 48.13 |
| Support Level | $20.63 | $3.25 |
| Resistance Level | $21.20 | $3.78 |
| Average True Range (ATR) | 0.52 | 0.25 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 35.67 | 13.52 |
Price Performance
Historical ComparisonAbout JMSB John Marshall Bancorp Inc.
John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.